|
Borage Oil and Ginkgo Biloba (EGb 761) in Asthma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Borage Oil and Ginkgo Biloba (EGb 761) in Asthma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Borage Oil and Ginkgo Biloba (EGb 761) in Asthma Clinical research trials and Borage Oil and Ginkgo Biloba (EGb 761) in Asthma health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Borage Oil and Ginkgo Biloba (EGb 761) in Asthma. Borage Oil and Ginkgo Biloba (EGb 761) in Asthma Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Borage Oil and Ginkgo Biloba (EGb 761) in Asthma clinical trial. Human subjects often get the best healthcare possible for their Borage Oil and Ginkgo Biloba (EGb 761) in Asthma condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Borage Oil and Ginkgo Biloba (EGb 761) in Asthma  Borage Oil and Ginkgo Biloba (EGb 761) in Asthma
Borage Oil and Ginkgo Biloba (EGb 761) in Asthma
For Condition: Asthma
Status: Recruiting
Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) ,
Synopsis: This study will assess clinical efficacy and/or adverse effects of dietary borage oil (which contains gamma-linolenic acid [GLA]) and Ginkgo biloba in patients with mild persistent to moderate asthma.
Details: The concept of asthma as a condition in which acute and chronic inflammatory changes in airways play a fundamental role is well established. The role of leukotrienes as a crucial element of these inflammatory processes is supported by abundant laboratory and clinical evidence. There is a potential for herbal medicinal approaches to ameliorate leukotriene-mediated inflammation in asthma based on data from the literature and our laboratory. Studies suggest that dietary GLA, found in borage and evening primrose oils, is unique among the (n-6) polyunsaturated fatty acid family members (linolenic acid, GLA and arachidonic acid) in its potential to attenuate inflammatory processes. For instance, there are randomized, placebo-controlled trials (RCT) demonstrating efficacy of dietary GLA in treating patients with rheumatoid arthritis and active synovitis. Ginkgo biloba, a flavonoid-rich extract of leaves of the Ginkgo biloba tree, has been studied in one RCT with asthma patients and is recommended by complementary and alternative practitioners as treatment for allergic inflammation and asthma. Ginkgo biloba supplements have no known adverse effects. We will assess clinical efficacies and/or adverse effects of dietary borage oil and Ginkgo biloba in patients with asthma in a 17 month RCT. We also propose to delineate whether or not the clinical course of treatment correlates with suppression of leukotriene B4 (LTB4), LTC4 and LTD4 generated by activated polymorphonuclear cells. Additionally, in the Ginkgo biloba arms of study, the in vitro/ex vivo inhibition of histamine release will be assayed, since one of its major constituents, quercetin, is known to be structurally related to cromolyn sodium and has been shown in vitro studies to exhibit similar activities. Furthermore, anti-inflammatory activities of Ginkgo biloba will be compared to those of some of its individual constituents in a series of in vitro experiments. It is hoped that findings from these studies will evolve relatively non-toxic therapeutic alternatives for attenuating bronchial hyperresponsiveness and inflammation in patients with asthma.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 16 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Symptoms (cough, wheeze, chest tightness) consistent with the National Asthma Education Program (NAEP) guidelines for mild persistent to moderate asthma Exclusion Criteria: - Severe asthma or mild intermittent asthma by NAEP revised guidelines - History of vasovagal reactions (nausea, dizziness, flushed/warm) upon having blood drawn - Pregnancy or lactation - History of emergency room care in the last 6 months - History of hospitalization - Use of prednisone in the past 3 months - Concurrent pulmonary disease: pulmonary hypertension, cystic fibrosis, sarcoidosis, bronchiectasis, hypersensitivity pneumonitis, restrictive lung disease - Cigarette smoking within the past 1 year; over 10-pack year history of cigarette smoking in ex-smokers - Recent (within one month) upper or lower respiratory tract infection - The following concurrent medical diagnoses: alcoholism, coronary artery disease, diabetes, HIV infection, chronic hepatitis, uncontrolled hypertension, or a psychiatric disorder that is judged to make full participation difficult - Use of prednisone in the past 3 months; current use of zileuton (leukotriene receptor antagonists are allowed) or theophylline - Use of dietary supplements (except for standard dose multiple vitamins such as One-a-day or Centrum) including herbal supplements, mega dose of multiple vitamins/antioxidants, magnesium, fish oil, borage oil, evening primrose oil, black currant oil, fungal oil, G. biloba, quercetin, or mega intake of garlic or onion (subjects will be asked to stop such therapies as a requirement of enrollment) - Ongoing use of homeopathic remedies or acupuncture, acupressure, therapeutic massage (subjects will be asked to stop such therapies as a requirement of enrollment)
Total Enrollment: 280
Location and Contact Information:
University of California, Davis *Recruiting*
Sacramento, California, 95817
United States
Recruiting Merrill Gershwin 530-752-2884
Additional Information:
Study ID Numbers: 1 R01 AT00637-02;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029679
Other Asthma Studies:
1. Clinical Trial of Acid Reflux Therapy in Asthma
2. Randomized Trial to Reduce Environmental Tobacco Smoke in Children with Asthma
3. Mechanisms of Allergen Immunotherapy
4. Intervention for Hispanic Children with Asthma
5. Early Risk Predictors For Chronic Pulmonary Disease
Related Studies:
Other Asthma Clinical Trials
Other California Clinical Trials
Other Sacramento Clinical Trials
Borage Oil and Ginkgo Biloba (EGb 761) in Asthma
|
|
|
|
|
|
|
|
